Clinical Trials
4 trialsNCT02518555 2026-04-06
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT05170399 2026-02-05
Vaccine Responses in Patients With B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 4 Recruiting
NCT04484532 2023-06-06
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Completed
NCT02747407 2021-10-29
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
Wake Forest University Health Sciences
Completed